Today techs Palisade Bio Declares Inducement Grants Below Nasdaq

today techs

Carlsbad, CA, Sept. 23, 2022 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI), a medical stage biopharmaceutical firm advancing therapies for acute and continual gastrointestinal (GI) problems, at present introduced that it had made fairness grants to 2 new workers below its 2021 Inducement Plan.

On August 29, today techs 2022, the Firm’s Compensation Committee granted choices to 2 new non-executive workers masking an mixture of 93,000 shares of the Firm’s widespread inventory as materials inducements to employment in accordance with Nasdaq Itemizing Rule 5635(c)(4).

The choices have an train worth equal to the closing worth of the Firm’s widespread inventory on the date of grant. The choices granted to every worker vest in equal proportions every quarter for 3 years. In all instances, the choices are contingent on every worker’s continued service with the Firm on the relevant vesting date.

About Palisade Bio

Palisade Bio is a late-stage biopharmaceutical firm centered on growing therapeutics that defend the integrity of the intestinal barrier. The Firm makes use of over three a long time of analysis and established science that hyperlinks the position of intestinal barrier biology and human illness to develop novel therapeutics that focus on and enhance the integrity of the intestinal barrier.

The Firm’s lead program, LB1148, is a broad-spectrum serine protease inhibitor which acts to neutralize digestive enzymes, today techs doubtlessly decreasing intestinal harm. In a number of medical research, LB1148 has demonstrated constructive leads to accelerating the time to return of postoperative bowel perform, and the Firm just lately introduced evaluation that LB1148 diminished the incidence and severity of post-surgical stomach adhesions. LB1148 is presently being evaluated in a Section 3 medical examine for accelerating the return of postoperative bowel perform and in a Section 2 examine for the prevention of post-surgical stomach adhesions.

The Firm believes that today techs addressing the disruption of the intestinal barrier has the potential to essentially change the best way ailments are handled and to ascertain new requirements of affected person care. For extra info, please go to www.palisadebio.com.

Ahead Trying Statements
This communication comprises “forward-looking” statements for functions of the secure harbor provisions of the Personal Securities Litigation Reform Act of 1995. Ahead-looking statements embrace statements relating to Palisade’s intentions, beliefs, projections, outlook, analyses or present expectations regarding, amongst different issues: the potential to essentially change the best way ailments are handled, the completion of enrollment for the Section 3 examine, the potential for the statistically important Section 3 knowledge to permit for NDA approval, and the potential for LB1148 to ascertain the usual of care, if accepted. Any statements contained on this communication that aren’t statements of historic reality could today techs also be deemed to be forward-looking statements. These forward-looking statements are based mostly upon Palisade’s present expectations. Ahead-looking statements contain dangers and uncertainties. Palisade’s precise outcomes and the timing of occasions might differ materially from these anticipated in such forward-looking statements on account of these dangers and uncertainties, which embrace, with out limitation, the corporate’s means to advance its medical packages, the unsure and time-consuming regulatory approval course of; the corporate’s means to realize extra financing to fund medical improvement and the corporate’s means to adjust to the continued itemizing necessities for Nasdaq. Further dangers and uncertainties could be present in Palisade Bio’s Quarterly Report on Type 10-Q for the quarter ended June 30, 2022. Palisade expressly disclaims any obligation or enterprise to launch publicly any updates or revisions to any forward-looking statements contained herein to mirror any change in Palisade’s expectations with regard thereto or any change in occasions, circumstances or circumstances on which any such statements are based mostly.

today techs

Investor Relations Contact
JTC Staff, LLC
Jenene Thomas
833-475-8247
PALI@jtcir.com

Supply: Palisade Bio

today techs
today techs

Be the first to comment

Leave a Reply

Your email address will not be published.


*